Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Proteomics|March 28, 2013
Current status and advances in quantitative proteomic mass spectrometryValerie C Wasinger, Ming Zeng, Yunki Yau
Alimentary Pharmacology & Therapeutics|June 21, 2021
Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) studyYanna Ko, Sudarshan Paramsothy, Yunki Yau, et al.
Journal of Gastroenterology and Hepatology|March 16, 2013
Proteomics and metabolomics in inflammatory bowel diseaseYunki Yau, Rupert W Leong, Ming Zeng, et al.
Scandinavian Journal of Gastroenterology|January 21, 2022
Reflux scintigraphy in gastro-esophageal reflux disease: a comparison study with 24 hour pH-impedance monitoringLisa S E Shim, Meng C Ngu, Yunki Yau, et al.
Digestive Diseases and Sciences|July 19, 2017
Proteomics in Inflammatory Bowel Disease: Approach Using Animal ModelsFadi H Mourad, Yunki Yau, Valerie C Wasinger, et al.
International Journal of Molecular Sciences|December 11, 2022
Tryptophan Metabolism 'Hub' Gene Expression Associates with Increased Inflammation and Severe Disease Outcomes in COVID-19 Infection and Inflammatory Bowel DiseaseSonia Bustamante, Yunki Yau, Victoria Boys, et al.
Gastroenterology|January 28, 2017
Full-Spectrum Endoscopy Improves Surveillance for Dysplasia in Patients With Inflammatory Bowel DiseasesRupert W Leong, Marie Ooi, Crispin Corte, et al.
Molecular & Cellular Proteomics : MCP|November 5, 2015
Low Mass Blood Peptides Discriminative of Inflammatory Bowel Disease (IBD) Severity: A Quantitative Proteomic PerspectiveValerie C Wasinger, Yunki Yau, Xizi Duo, et al.
Journal of Crohn'S & Colitis|March 20, 2020
Knowledge and Attitudes Towards Pregnancy in Females with Inflammatory Bowel Disease: An International, Multi-centre StudyRobyn Laube, Yunki Yau, Christian P Selinger, et al.
European Journal of Gastroenterology & Hepatology|May 5, 2018
Entyvio lengthen dose-interval study: lengthening vedolizumab dose interval and the risk of clinical relapse in inflammatory bowel diseaseWebber Chan, Nicole Lynch, Peter Bampton, et al.
Pageof 1